Skip to Content
77 Mass Ave

Closing a Back Door for Cancer

Drugs that block a new target gene could make chemotherapy more effective.
December 17, 2013

About half of all cancer patients have a mutation in a gene called p53, which codes for a tumor-suppressing protein that controls cell division. That mutation allows tumors to continue growing even after chemotherapy damages their DNA.

a micrograph
A micrograph shows cells with abnormal p53 expression (brown) in a brain tumor.

A new study from MIT biologists has found that tumor cells with mutated p53 can be made much more vulnerable to chemotherapy by blocking another gene, called MK2. In a study of mice, tumors lacking both p53 and MK2 shrank dramatically when treated with the drug cisplatin, while tumors with functional MK2 kept growing.

The new findings suggest that giving cancer patients a combination of a DNA-damaging drug and an MK2 inhibitor could be very effective, says biology professor Michael Yaffe, senior author of a Cell Reports paper describing the research. He notes that while several drugs that inhibit MK2 are now in clinical trials to treat inflammatory diseases such as arthritis and colitis, they have never been tested as possible cancer treatments.

Before cell division begins, p53 checks the cell’s DNA and initiates repair, if necessary. If DNA damage is too extensive, p53 forces the cell to undergo programmed cell death, or apoptosis. Tumors that lack p53 can avoid this fate.

“Usually p53 is the main driver of cell death, and if cells lose this pathway they become very resistant to different treatments,” says Koch Institute postdoc ­Sandra Morandell, who was lead author of the paper.

Yaffe’s lab had previously discovered that the MK2 gene helps counteract the effects of chemotherapy in cancer cells with mutated p53. When the drugs damage cancer cells’ DNA, MK2 puts the brakes on the cell division cycle, giving them time to repair the damage before dividing. “Our data suggested if you block the MK2 pathway, tumor cells wouldn’t recognize that they had DNA damage and they would keep trying to divide despite having DNA damage, and they would end up committing suicide,” Yaffe says.

In the new study, the researchers used a strain of mice that are genetically programmed to develop non-small-cell lung tumors. They further engineered the mice so that the MK2 gene could be turned on or off. That way, tumors with and without MK2 could be studied in the same animal.

Before treatment, tumors lacking both MK2 and p53 grew faster than tumors with MK2. This suggests that treating tumors with an MK2 inhibitor alone would do more harm than good, possibly increasing the growth rate by taking the brakes off the cell cycle. But cisplatin shrank the tumors lacking MK2 without affecting the others.

The researchers have found similar results with cancer cells grown in the lab from bone, cervical, and ovarian tumors. They are now studying mouse models of colon and ovarian cancer.

Keep Reading

Most Popular

Workers disinfect the street outside Shijiazhuang Railway Station
Workers disinfect the street outside Shijiazhuang Railway Station

Why China is still obsessed with disinfecting everything

Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Europe's AI Act concept
Europe's AI Act concept

A quick guide to the most important AI law you’ve never heard of

The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.